19
Aug

Novartis is forging ahead with a prospective stem cell biotech buyout, agreeing to pay $35 million to grab a sizable equity stake in Gamida Cell while executing a short term option deal that will allow the pharma giant the right to gobble up the company for another $600 million split up between a $165 million upfront payout with the rest up for grabs in development and sales milestones.

…read more

Source: Novartis slashes ante, inks another Gamida Cell buyout pact in $635M leukemia deal

    

0 No comments